KR20030022500A - Composition of healthfood for skin-whitening - Google Patents
Composition of healthfood for skin-whitening Download PDFInfo
- Publication number
- KR20030022500A KR20030022500A KR1020010055613A KR20010055613A KR20030022500A KR 20030022500 A KR20030022500 A KR 20030022500A KR 1020010055613 A KR1020010055613 A KR 1020010055613A KR 20010055613 A KR20010055613 A KR 20010055613A KR 20030022500 A KR20030022500 A KR 20030022500A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- skin
- vitamin
- placenta
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 235000013402 health food Nutrition 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 54
- 210000002826 placenta Anatomy 0.000 claims abstract description 26
- 235000010841 Silybum marianum Nutrition 0.000 claims abstract description 23
- 241000320380 Silybum Species 0.000 claims abstract description 21
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 15
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract 2
- 230000019612 pigmentation Effects 0.000 claims description 12
- 235000003687 soy isoflavones Nutrition 0.000 claims description 10
- 239000007901 soft capsule Substances 0.000 claims description 9
- 244000025012 Spondias pinnata Species 0.000 claims description 7
- 235000005658 Spondias pinnata Nutrition 0.000 claims description 7
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 13
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 abstract description 13
- 235000008696 isoflavones Nutrition 0.000 abstract description 13
- 235000010469 Glycine max Nutrition 0.000 abstract description 11
- 244000068988 Glycine max Species 0.000 abstract description 7
- 206010042496 Sunburn Diseases 0.000 abstract description 6
- 230000002087 whitening effect Effects 0.000 abstract description 6
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 abstract description 5
- 208000003351 Melanosis Diseases 0.000 abstract description 2
- 230000002411 adverse Effects 0.000 abstract description 2
- 235000020727 milk thistle extract Nutrition 0.000 abstract description 2
- 239000007903 gelatin capsule Substances 0.000 abstract 2
- 206010008570 Chloasma Diseases 0.000 abstract 1
- 229940096421 milk thistle extract Drugs 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 14
- 230000006872 improvement Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 239000000843 powder Substances 0.000 description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 9
- 229930003268 Vitamin C Natural products 0.000 description 9
- 235000019154 vitamin C Nutrition 0.000 description 9
- 239000011718 vitamin C Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 8
- 150000002515 isoflavone derivatives Chemical class 0.000 description 8
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 8
- 229960004245 silymarin Drugs 0.000 description 8
- 235000017700 silymarin Nutrition 0.000 description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960000342 retinol acetate Drugs 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 235000019173 retinyl acetate Nutrition 0.000 description 4
- 239000011770 retinyl acetate Substances 0.000 description 4
- 235000020712 soy bean extract Nutrition 0.000 description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000017657 Menopausal disease Diseases 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- IMWCPTKSESEZCL-SPSNFJOYSA-H (e)-but-2-enedioate;iron(3+) Chemical compound [Fe+3].[Fe+3].[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O IMWCPTKSESEZCL-SPSNFJOYSA-H 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000010369 Cascara Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000556215 Frangula purshiana Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 acidulants Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229940071704 cascara sagrada Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000481 effect on pigmentation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940074122 phyllanthus emblica fruit extract Drugs 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 대두에서 추출한 이소플라본, 플라센타추출물, 암라추출물과 밀크씨슬을 함유하는 것을 특징으로 하는 피부 미백용 건강식품에 관한 것으로서, 보다 상세하게는 기미, 노인성 반점과 햇볕에 의한 그을림 등의 색소침착 증상을 개선하는 조성물에 관한 것이다.The present invention relates to a skin whitening health food comprising isoflavones, placenta extracts, amla extracts, and milk thistles extracted from soybeans, and more specifically, pigments such as blemishes, senile spots and sunburns. A composition for improving the symptoms of deposition.
기미, 노인성 반점과 햇볕에 의한 그을림 등과 같은 색소침착증상은 아름답기를 갈망하는 여성들과 젊게 보이고자 하는 사람들에게는 심각한 문제로 제기되어 오고 있다.Pigmentation symptoms such as blemishes, senile spots and sunburn have been a serious problem for women longing for beauty and those who want to look young.
이런 문제를 해결하기 위하여 사용된 유기화합물로는 하이드로퀴논 등의 표백물질이 있었으나 사용이 금지되었고, 코직산(kojic acid)(일본특허출원 평1-161155호) 등과 같이 티로시나제(tyrosinase)를 억제하여 멜라닌 생성을 억제하는 물질, 녹차추출물 또는 토코페롤, 비타민 C와 같은 항산화제를 함유한 화장품은 이 분야에서 잘 알려진 사실이다.The organic compounds used to solve this problem were bleaching substances such as hydroquinone, but they were prohibited to use, and melanin was inhibited by inhibiting tyrosinase such as kojic acid (Japanese Patent Application No. 11-161155). Production inhibitors, green tea extracts or cosmetics containing antioxidants such as tocopherols and vitamin C are well known in the art.
이와 같이 색소침착증상을 개선하는 기존의 화장품들의 기능성 물질은 피부를 통하여 흡수되어야만 작용이 나타나는 것이므로 피부가 배설기관이라는 근본적 이유 때문에 피부를 통한 흡수가 불충분하여 그 효과가 충분하지 못하다는 문제점과 한계점들이 있다. 따라서 색소침착증상에 대하여 우수한 개선효과를 나타내게 하는 새로운 시도 즉 미백효과 기능을 나타내는 소재를 경구적으로 섭취하여 피부 미백효과를 발휘하는 제품 개발이 절실히 요구되고 있다.As functional substances of conventional cosmetics that improve pigmentation symptoms appear only when they are absorbed through the skin, the effect is not sufficient because the absorption is through the skin due to the fundamental reason that the skin is excretory organs. have. Therefore, there is an urgent need to develop a product that exerts oral ingestion of a material that exhibits a whitening effect or a skin whitening effect by showing an excellent improvement effect on pigmentation symptoms.
본 발명자는 부작용이 없이 안전성이 높으면서 색소침착증상을 개선하는 효과를 나타내는 소재와 제품을 개발하고자 많은 연구를 수행한 결과, 대두에서 추출한 이소플라본, 플라센타추출물, 암라추출물과 밀크씨슬을 함유하는 조성물이 부작용이 없으면서 색소침착증상을 개선하는 우수한 효과를 나타냄을 확인하여 본 발명을 완성하였다.The present inventors conducted a number of studies to develop a material and a product having a high safety without side effects and improving the pigmentation symptoms, as a result, a composition containing isoflavones, placenta extract, amla extract and milk thistle extracted from soybean The present invention was completed by confirming the excellent effect of improving the pigmentation symptoms without this side effect.
따라서 본 발명의 목적은 대두에서 추출한 이소플라본, 플라센타추출물, 암라추출물과 밀크씨슬을 함유함을 특징으로 하는 색소침착증 개선제를 제공하는데 있다.Accordingly, it is an object of the present invention to provide a pigmentation-improving agent characterized in that it contains isoflavones, placenta extracts, amra extracts and milk thistles extracted from soybeans.
본 발명의 또 다른 목적은 대두에서 추출한 이소플라본, 플라센타추출물, 암라추출물과 밀크씨슬을 함유함을 특징으로 하는 정제, 캅셀제, 과립제, 환제, 액제와 같은 색소침착증 개선용 경구 투여 제제를 제공하는 데 있다.Still another object of the present invention is to provide an oral dosage form for improving pigmentation, such as tablets, capsules, granules, pills, and liquids, comprising isoflavones, placenta extracts, amra extracts, and milk thistles extracted from soybeans. There is.
본 발명은 대두에서 추출한 이소플라본, 플라센타추출물, 암라추출물과 밀크씨슬을 함유하는 것을 특징으로 하는 피부 미백용 건강식품 즉 기미, 노인성 반점과 햇볕에 의한 그을림 등의 색소침착 증상을 개선하는 조성물에 관한 것이다.The present invention relates to a composition for improving pigmentation symptoms such as isoflavones, placenta extracts, amla extracts, and milk thistle extracts from soybeans, ie blemishes, senile spots and sunburn. It is about.
얼굴과 피부 상태는 신체 내부로부터 영향을 많이 받는다. 그러므로 건강한 얼굴과 피부는 건강한 육체에 기인하는 것이므로 미용효과와 건강효과가 동시에 나타나도록 하는 것이 더욱 바람직하다.Facial and skin conditions are heavily influenced from inside the body. Therefore, a healthy face and skin is due to a healthy body, so it is more desirable to have both a cosmetic effect and a health effect.
혈행 촉진작용, 세포분열 촉진작용, 신진대사 촉진작용, 활성산소 제거작용, 항염증작용, 항알러지작용, 유해 물질 생성억제 및 제거작용 등으로 인한 신체 자유치 유력 증강, 호르몬 불균형 개선 등이 복합적으로 작용하여야만 피부를 건강하게 하고 젊은 상태로 유지하며 미백효과도 극대화 할 수 있다. 이런 목적을 달성하기 위하여는 단일 성분으로는 부족하여 각각의 효능을 갖는 몇 가지 성분을 배합함으로써 소기의 목적을 달성할 수 있음을 알게 되었다.Increasing the potency of the body's free teeth by improving blood circulation, promoting cell division, promoting metabolism, removing free radicals, anti-inflammatory, anti-allergic, inhibiting and removing harmful substances, and improving hormone imbalance. It should work to keep skin healthy and young and maximize the whitening effect. In order to achieve this purpose, it has been found that the desired purpose can be achieved by combining several components having respective effects due to a lack of a single component.
소 플라센타추출물은 옛날부터 불노장수약제로 신중히 사용하였고, 현대에도 의약품 및 화장품 소재로 그 유용성을 인정받고 있는 동물성 자양강장 생약이다. 플라센타에는 3대영양소(아미노산과 단백질, 지질, 당질) 외에 여러 종류의 효소, 비타민, 미네랄 외에 신비적인 힘을 가진 특이한 물질이 함유되어있어 신체의 자연 치유력을 높인다. 구체적 효능으로 혈행을 좋게 하여 피부신진대사 촉진, 피부의 세포분열을 촉진, 자극으로부터 피부의 염증을 예방, 활성산소의 활동을 억제, 멜라닌 색소의 생성과 침착을 억제, 자율신경과 호르몬의 바란스를 조절, 간장 등의 장기 조직세포재생을 촉진하여 기능을 강화, 조혈조직을 자극하여 조혈작용, 창상 회복 및 글리코겐 형성을 빠르게 하므로 간 경변 예방, 기미, 주근깨개선, 빈혈치료, 갱년기장애 개선, 생리불순과 냉증 개선, 허약체질과 병중 병후체력회복, 상습적 변비, 정력감퇴, 암 예방, 노화지연, 저항력 증가, 알러지 체질개선 등에 응용하고 있는 소재이다.Bovine placenta extract has been used carefully as a vegetative medicinal herb since ancient times, and is an animal nourishment tonic herbal medicine that has been recognized for its usefulness as a medicine and cosmetic material in modern times. In addition to the three major nutrients (amino acids, proteins, lipids, sugars), placenta contains a variety of enzymes, vitamins, and minerals, as well as unique substances with mysterious powers that enhance the body's natural healing power. The specific effect is to improve blood circulation, promote skin metabolism, promote skin cell division, prevent skin inflammation from stimulation, inhibit the activity of free radicals, inhibit the production and deposition of melanin pigment, balance of autonomic nerve and hormone Enhance function by promoting long-term tissue cell regeneration such as regulation, liver, and stimulating hematopoietic tissue to accelerate hematopoietic action, wound recovery and glycogen formation, thus preventing liver cirrhosis, blemishes, freckle improvement, anemia treatment, menopausal disorder improvement, menstrual disorder It is applied to improvement of hyperthermia, weakness and sickness after illness, rehabilitation of habitual constipation, loss of energy, prevention of cancer, aging delay, increased resistance, and allergy improvement.
암라추출물은 Phyllanthus emblica 과실 추출물로서 인도의 전통 의학서 아유베다(Ayurveda)에 수재되어 있는 건강과실로 고함량의 비타민 C는 레몬의 10배, 폴리페놀은 적색와인의 30배나 풍부한 피부와 건강 보호인자를 대량 섭취할 수 있는 신소재이다. 피부와 건강에 대한 5대 효과로 1) 활성산소 억제 : 세포의 손상을 방지하여 노화 방지효과, 2) 히아루론산 분해 저해 : 보습성분을 보호한다. 3) 콜라겐의 보호 : 피부에 힘과 탄력을 주며 피부 노화를 방지한다. 4) 알러지-염증 억제 : 피부를 트라블로부터 보호, 5) 히스타민의 유리 억제 : 알러지 증상을 완화하는 작용이 알려져 있다.Amra extract is a phyllanthus emblica fruit extract, a health fruit found in Ayurveda, a traditional Indian medicine. It contains 10 times as much vitamin C as lemon and 30 times as much polyphenol as red skin. It is a new material that can be consumed in large quantities. With 5 major effects on skin and health: 1) inhibition of free radicals: anti-aging effect by preventing cell damage, 2) inhibition of decomposition of hyaluronic acid: protection of moisturizing ingredients. 3) Protection of collagen: It gives skin strength and elasticity and prevents skin aging. 4) Allergy-Inflammation Inhibition: Protects skin from trabble, 5) Free Inhibition of Histamine: It is known to alleviate allergy symptoms.
대두이소플라본은 대두추출물을 정제한 것으로 식물성 에스트로겐이라고도 하며 여성호르몬 에스트로겐이 신체에 갖는 항상성을 유지해주므로 여성호르몬 부족이나 불균형으로 인하여 발생하는 피부 및 건강에 대한 증상을 개선할 수 있다.Soy isoflavone is a refined soybean extract, also known as phytoestrogens, and maintains the homeostasis of female hormone estrogen in the body, thereby improving skin and health symptoms caused by female hormone deficiency or imbalance.
갱년기 장애 치료 및 예방 효과, 만성 질환 예방 및 치료 효과 :혈중 콜레스테롤저하작용, 동맥경화, 관상동맥질환 억제작용, 항암작용, 골다공증 치료작용이 임상적으로 확인되어 있다.Treatment and prevention of menopausal disorders, prevention and treatment of chronic diseases: Lowering blood cholesterol, arteriosclerosis, coronary artery disease suppression, anticancer, osteoporosis treatment has been clinically confirmed.
밀크씨슬은 2000년 전 이상부터 유럽의 민간약으로 사용된 약용식물 Silybum marianum의 추출물로 약물중독으로 인한 간장 장해의 치료약, 만성간염과 간경변의 보조치료약, 담낭, 소화기관, 비장 등의 질병, 모유부족에 널리 사용되고 있는 생약이다. 밀크씨슬은 활성성분으로 실리마린이 함유된 것으로 1) 간세포 막 안정화작용 : 간장 내 글루타치온 농도를 50 % 증가, 슈퍼옥사이드 디스뮤타제 활성 상승작용, 비타민 E 보다 10배 더 강한 항산화활성에 의한 활성산소 제거능력의 강화, 세포막 상의 수용체를 조정하여 알콜, 사염화탄소, 톡신, 각종 공해물질등 독성물질이 세포내로 들어가는 것을 방지하고 대사되는 과정에서 발생되는 자유분자기 등 유해물질을 억제하여 간 세포를 보호하고 세포막을 안정화시킨다.Milk Thistle is an extract of Silybum marianum, a medicinal plant that has been used as a folk medicine in Europe for more than 2000 years. It is a medicine for the treatment of liver damage caused by drug poisoning, adjuvant medicine for chronic hepatitis and cirrhosis, gallbladder, digestive system, spleen and other diseases. It is a herb widely used in tribes. Milk Thistle contains Silymarin as an active ingredient 1) Hepatocellular membrane stabilization: 50% increase in glutathione concentration in liver, synergistic superoxide dismutase activity, active oxygen by 10 times stronger antioxidant activity than vitamin E It enhances the ability to remove, adjusts receptors on the cell membrane to prevent the entry of toxic substances such as alcohol, carbon tetrachloride, toxin and various pollutants into the cell, and protects liver cells by inhibiting harmful substances such as free molecules generated during metabolism. Stabilize the cell membrane.
2) 손상된 간세포 재생작용 : RNA합성 촉진, 단백질합성을 촉진하여 음주, 바이러스 감염으로 기능이 저하된 간세포의 효소, 구조 단백질을 정상으로 회복시킨다.2) Impaired hepatocyte regeneration: Promotes RNA synthesis and protein synthesis to restore the enzymes and structural proteins of hepatocytes that have degraded due to drinking and virus infection.
간세포의 재생은 촉진하지만 암세포 증식을 촉진하지 않는다.Promotes regeneration of hepatocytes but does not promote cancer cell proliferation.
알콜성 간염, 약물로 인한 간장해, 간경변, 환경공해물질과 작업환경 중의 물질에 의한 간장해, 여러 가지 원인에 의한 간장해로 위무력감, 피로, 구토증, 불쾌감, 가려움 증상을 개선한다. 간 기능을 개선함으로써 얼굴과 피부를 건강하고 미백 상태를 유지할 수 있을 것으로 기대된다.Alcoholic hepatitis, drug-induced liver damage, cirrhosis, environmental pollution and liver damage caused by substances in the working environment, and liver damage caused by various causes improve stomach discomfort, fatigue, nausea, discomfort and itching. Improving liver function is expected to keep your face and skin healthy and whitened.
대두이소플라본, 플라센타추출물, 암라추출물, 밀크씨슬은 각각 건강식품의 소재로 사용된적은 있으나 이들의 조성물을 만들므로써 기미, 노인성 반점과 햇볕에 의한 그을림 등의 색소침착증상을 현저하게 개선하는 용도로 사용한 경우는 없었으므로 본 발명의 조성물은 신규한 것이다.Soy isoflavones, placenta extracts, amra extracts, and milk thistles have been used as health foods, but their compositions are used to significantly improve pigmentation symptoms such as blemishes, senile spots and sunburn. Since there was no use, the composition of the present invention is novel.
본 발명의 조성불에 결명자추출물이나 카스카라사그라다추출물 등 장운동개선작용이 있는 성분, 비타민 C, E, B군과 A, 아연, 철분과 같은 미네랄 성분을 추가하면 미백효과를 보강할 수 있다.The composition of the present invention can add a whitening effect by adding components such as vitamin C, E, B group and A, zinc, iron, etc., which have the effect of improving bowel movement, such as the extract of Cassava or Cascara sagrada extract.
이하 본 발명을 상세하게 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.
본 발명은 대두이소플라본, 플라센타추출물, 암라추출물과 밀크씨슬을 함유하는 것을 특징으로 하는 부작용이 없으면서 높은 개선효과를 나타내는 색소침착증상개선용 조성물에 관한 것이다.The present invention relates to a composition for improving pigmentation symptom improvement without high side effects, characterized by containing soy isoflavones, placenta extracts, Amra extracts and milk thistle.
대두이소플라본은 대두추출물로 이소플라본이 10내지 80% 함유된 것을 사용하는 것이 바람직하며 시중에 유통되는 것을 사용할 수 있다. 프라센타추출물은 소나 양의 태반을 물로 추출하여 분말화한 것을 사용한다. 암라추출물은 Phyllanthus emblica 과일을 물 또는 함수 알콜로 추출하여 1:1 내지 7:1로 분말화한 것을 사용한다. 밀크씨슬은 Silybum marianum의 추출물로 실리마린을 20% 내지 85% 함유하는 것을 사용한다.Soy isoflavones are preferably soybean extract containing 10 to 80% of isoflavones can be used in the market. Placenta extract is used by powdering the placenta of cows or sheep with water. Amla extract is obtained by pulverizing Phyllanthus emblica fruits with water or hydrated alcohol from 1: 1 to 7: 1. Milk Thistle is an extract of Silybum marianum, which contains 20% to 85% of silymarin.
본 발명의 조성비율은 대두이소플라본 1중량비에 대하여 플라센타추출물은1 내지 10중량비, 암라추출물은 0.5 내지 10중량비, 밀크씨슬은 0.5 내지 10중량비로 사용하는 것이 바람직하다. 필요에 따라서는 경구 투여 제제에 통상적으로 사용되는 첨가제, 유화제, 활탁제, 점착제, 산미제, 방향제 등을 이용하여 정제, 캅셀제, 연질캅셀제, 과립제, 액제, 환제 같은 경구 투여 제제를 제조하여 섭취 할 수 있다.The composition ratio of the present invention is preferably 1 to 10 weight ratio of placenta extract, 0.5 to 10 weight ratio of Amra extract, and 0.5 to 10 weight ratio of milk thistle with respect to 1 weight ratio of soy isoflavones. If necessary, oral dosage preparations such as tablets, capsules, soft capsules, granules, solutions, and pills may be prepared and consumed using additives, emulsifiers, suspending agents, pressure-sensitive adhesives, acidulants, and fragrances commonly used in oral dosage forms. Can be.
본 발명의 대두이소플라본은 이소플라본이 하루에 30 내지 100mg이 섭취되도록 한 조성물을 1일 2 ∼ 3회 섭취하는 것이 바람직하다.Soy isoflavones of the present invention is preferably ingested 2 to 3 times a day so that isoflavones are ingested 30 to 100mg per day.
이하, 본 발명을 바람직한 실시예에 의거하여 보다 상세히 설명하고자 하나, 이것은 본 발명의 이해를 돕기 위한 것일 뿐 본 발명의 범위를 어떤 식으로든지 제한하고자 하는 것은 아니다.Hereinafter, the present invention will be described in more detail based on the preferred embodiments, which are intended to aid the understanding of the present invention and are not intended to limit the scope of the present invention in any way.
[실시예]EXAMPLE
이하 실시예에 사용한 플라센타추출물은 소 태반 물 추출물분말(일본산), 대두추출물분말은 이소플라본 30%인 국산, 암라추출물은 물추출물분말로 4:1로 농축된 것, 밀크씨슬은 실리마린 20%, 80%인 것을 시중에서 구입하여 사용하였다.Placenta extract used in the following examples are bovine placenta water extract powder (Japan), soybean extract powder is domestically 30% isoflavones, Amla extract is water extract powder concentrated to 4: 1, milk thistle silymarin 20 % And 80% of what was purchased commercially was used.
[실시예 1] 액제Example 1 Liquid
플라센타추출물 5.2g, 대두추출물분말(이소플라본 30%) 5g, 암라추출물 2.4g, 밀크씨슬(실리마린 20%) 1.4g, 비타민 C 5g, 비타민 B1 염산염 200mg, 비타민 B2 100mg, 트윈 80 2g을 정제수 500ml에 가한 후 50℃로 가온한 후 교반하여 가용화하여 액제를 제조하였다.Placenta extract 5.2g, soy extract powder (5% isoflavone) 5g, Amla extract 2.4g, milk thistle (20% silymarin) 1.4g, vitamin C 5g, vitamin B1 hydrochloride 200mg, vitamin B2 100mg, twin 80 2g After adding to 500ml it was warmed to 50 ℃ and solubilized by stirring to prepare a liquid.
[실시예 2] 과립제Example 2 Granules
플라센타추출 50g, 대두추출물분말 55g, 암라추출물 30g, 밀크씨슬(실리마린 80%) 40g, 비타민 E 분말(50%) 10g, 비타민 C 25g, 비타민 B1 염산염 1g, 비타민 B 0.8g, 니코틴산 아미드 5g, 비타민 B6 염산염 1.2g, 엽산 0.5g, 스테아린산마그네슘 1.5g, 산화아연 2g,푸마르산철 2g, 옥수수전분176g을 잘 혼합하고 통상의 방법 대로 과립제를 제조하였다.Placenta Extract 50g, Soy Extract Powder 55g, Amla Extract 30g, Milk Thistle (Silymarin 80%) 40g, Vitamin E Powder (50%) 10g, Vitamin C 25g, Vitamin B1 Hydrochloride 1g, Vitamin B 0.8g, Nicotinic Acid Amide 5g, 1.2 g of vitamin B6 hydrochloride, 0.5 g of folic acid, 1.5 g of magnesium stearate, 2 g of zinc oxide, 2 g of iron fumarate, and 176 g of corn starch were mixed well and granules were prepared according to a conventional method.
[실시예 3] 정제Example 3 Tablet
실시예 2에서 제조한 과립을 통상의 방법에 따라 타정하여 500mg 정제를 제조하였다.The granules prepared in Example 2 were compressed into tablets according to a conventional method to prepare 500 mg tablets.
[실시예 4] 경질캅셀제Example 4 Hard Capsule
플라센타추출물 45g, 대두추출불분말 50g, 암라추출물 30g, 밀크씨슬(실리마린 80%) 25g, 비타민 E 분말(50%) 50g, 비타민 C 50g, 산화아연 10g, 비타민 A 아세테이트분말 1g, 스테아린산마그네슘 2g, 미세결정셀룰로오스 37g을 잘 혼합하여 통상의 방법에 따라 경질캅셀에 400mg씩을 충진하여 캅셀제를 제조하였다.Placenta Extract 45g, Soybean Extract Powder 50g, Amla Extract 30g, Milk Thistle (Silymarin 80%) 25g, Vitamin E Powder (50%) 50g, Vitamin C 50g, Zinc Oxide 10g, Vitamin A Acetate Powder, Magnesium Stearate 2g , 37 g of microcrystalline cellulose were mixed well, and 400 mg of the hard capsule was filled in a conventional manner to prepare a capsule.
[실시예 5] 환제Example 5 Pill
플라센타추출물 45g, 대두추출물분말(이소플라본 30%) 50g, 암라추출물 30g, 밀크씨슬(실리마린 80%) 25g, 비타민 E 분말(50%) 50g, 비타민 C 50g, 산화아연 10g, 비타민 A 아세테이트분말 1g, 옥수수전분 37g, 벌꿀100g을 잘 혼합하여 통상의 방법에 따라 100mg 환제를 제조하였다.Placenta Extract 45g, Soy Extract Powder (Isoflavone 30%) 50g, Amla Extract 30g, Milk Thistle (Silymarin 80%) 25g, Vitamin E Powder (50%) 50g, Vitamin C 50g, Zinc Oxide 10g, Vitamin A Acetate Powder 1 g, corn starch 37 g, honey 100 g was mixed well to prepare a 100 mg pills according to a conventional method.
[실시예 6] 연질캅셀제Example 6 Soft Capsule
플라센타추출물 517g, 대두추출물분말(이소플라본 30%) 495g, 암라추출물분말331g, 밀크씨슬(실리마린 80%) 433g, 비타민 E 아세테이트 363g, 비타민 C 220g, 산화아연 165g, 비타민 B1 염산염 16.5g, 비타민 B2 16.5g, 니코틴산아미드 50g, 비타민 B6 염산염 16.5g, 비타민 A 아세테이트 3.3g, 엽산 2.2g, 레시틴 55g, 대두유 2596g, 황납 110g을 균질하게 혼합하고 통상의 방법에 따라 550mg 씩을 충진하여 연질캅셀제를 제조하였다.Placenta Extract 517g, Soy Extract Powder (Isoflavone 30%) 495g, Amla Extract Powder 331g, Milk Thistle (Silymarin 80%) 433g, Vitamin E Acetate 363g, Vitamin C 220g, Zinc Oxide 165g, Vitamin B1 Hydrochloride 16.5g, Vitamin B2 16.5g, nicotinic acid amide 50g, vitamin B6 hydrochloride 16.5g, vitamin A acetate 3.3g, folic acid 2.2g, lecithin 55g, soybean oil 2596g, lead 110g, homogeneously mixed and filled with 550mg each according to a conventional method to produce a soft capsule It was.
[참고예 1] 연질캅셀제Reference Example 1 Soft Capsule
플라센타추출물 517g, 비타민 E 아세테이트 363g, 비타민 C 220g, 산화아연 165g, 비타민 B1 염산염 16.5g, 비타민 B2 16.5g, 니코틴산아미드 50g, 비타민 B6염산염 16.5g, 비타민 A 아세테이트 3.3g, 엽산 2.2g, 레시틴 55g, 결정성셀룰로오스 1259g, 대두유 2596g, 황납 110g을 균질하게 혼합하고 통상의 방법에 따라 550mg 씩을 충진하여 연질캅셀제를 제조하였다.Placenta Extract 517g, Vitamin E Acetate 363g, Vitamin C 220g, Zinc Oxide 165g, Vitamin B1 Hydrochloride 16.5g, Vitamin B2 16.5g, Nicotinamide 50g, Vitamin B6 Hydrochloride 16.5g, Vitamin A Acetate 3.3g, Folic Acid 2.2g, Lecithin 55g , 1259 g of crystalline cellulose, 2596 g of soybean oil, and 110 g of lead were homogeneously mixed, and 550 mg of each was filled according to a conventional method to prepare a soft capsule.
[참고예 2] 연질캅셀제Reference Example 2 Soft Capsule
대두유를 550mg 씩 충진하여 연질캅셀을 제조하였다.Soybean oil was filled in 550mg each to prepare a soft capsule.
[실험예1] 기미 개선효과Experimental Example 1 Improvement
본 발명의 조성물의 기미에 대한 개선효과을 확인하기 위하여 기미를 가진 40∼60세의 여성 30명을 3군으로 나누어 실시예6, 참고예1, 참고예2에서 제조한 연질캅셀을 2개월간 1일 2회(아침식후, 저녁식후) 1회 2캅셀을 복용시켰다.In order to confirm the improvement effect on the blemishes of the composition of the present invention, the soft capsules prepared in Example 6, Reference Example 1, and Reference Example 2 were divided into three groups of 30 women aged 40 to 60 years with blemishes for 1 month for 2 months. Two capsules were taken twice (after breakfast and after dinner).
실험결과는 기미가 없어지는 것을 육안으로 관찰하여 다음과 같이 4가지 경우로 판정하였으며, 그 결과를 표1에 나타내었다.Experimental results were visually observed that disappearance was determined by four cases as follows, the results are shown in Table 1.
현저한 효과 기미 또는 노인성반점이 현저히 엷어져 없어Significant effect There are no noticeable thinning or senile spots
진 경우Jean
유효 상당히 효과가 있다고 판단되는 경우When it is judged to be effective effectively
약간 유효 간신히 색소 소실이 진행된 경우Slightly effective When the pigment disappears
무효 변화가 없는 경우If there is no invalid change
유효율은 약간유효 이상이 차지하는 비율로 하였다.The effective rate was taken as the ratio which a little more than effective.
본 발명에 의한 플라센타추출물, 대두이소플라본, 암라추출물, 밀크씨슬을 함유하는 조성물은 기미에 대하여 90%의 상승적으로 높은 개선효과를 나타내었다.The composition containing the placenta extract, soy isoflavone, Amla extract and milk thistle according to the present invention showed a synergistically high improvement effect of 90% against the blemishes.
[표 1] 기미 치료효과[Table 1] Blemish Treatment Effect
[실험예2] 노인성반점 개선효과Experimental Example 2 Improvement of Geriatric Spots
노인성 반점을 가진 60∼80세 여성 30명을 대상으로 2개월간 실험예1과 같은 방법으로 복용케하여 그 결과를 표 2에 나타내었다.Thirty 60-80 year old women with senile spots were administered in the same manner as in Experiment 1 for 2 months and the results are shown in Table 2.
[표 2] 노인성반점 개선효과[Table 2] Improvement of Geriatric Spots
상기 실험예에 나타낸 바와 같이 본 발명의 조성물은 기미에 90% 유효율, 노인성 반점에 대하여 80% 유효율로 우수한 개선효과를 나타내며 햇볕 그을림에 의한 피부색소침착증 개선도 기대되는 건강보조식품으로 사용할 수 있다.As shown in the experimental example, the composition of the present invention exhibits an excellent improvement effect at 90% effective rate, 80% effective rate for blemishes, and can be used as a dietary supplement that is expected to improve skin pigmentation due to sunburn.
본 발명의 조성물은 기미 개선효과가 있다고 알려져 있는 플라센타추출물에 비하여 현저한 개선효과가 나타나는 것은 플라센타추출물에 여성호르몬 역할을 하는 대두이소플라본과 암라추출물, 밀크씨슬이 첨가 됨으로써 이들 성분이 상승효과를 발휘하여 기미, 노인성 반점 등 색소침착증상을 개선하는 것으로 사료된다.The composition of the present invention exhibits a significant improvement over the placenta extract, which is known to have a blemish-improving effect, by adding soy isoflavone, amarula extract, and milk thistle, which act as female hormones to the placenta extract, thereby exerting a synergistic effect. It is thought to improve pigmentation symptoms such as blemishes and senile spots.
또한 본 발명의 조성물을 복용하는 동안 부작용으로 생각되는 증상은 전혀 발견되지 않았으므로 건강식품으로 널리 복용될 수 있을 만큼 매우 안전하다.In addition, while taking the composition of the present invention, no symptoms thought to be adverse effects were found to be very safe enough to be widely used as a health food.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010055613A KR20030022500A (en) | 2001-09-10 | 2001-09-10 | Composition of healthfood for skin-whitening |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010055613A KR20030022500A (en) | 2001-09-10 | 2001-09-10 | Composition of healthfood for skin-whitening |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030022500A true KR20030022500A (en) | 2003-03-17 |
Family
ID=27723343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010055613A KR20030022500A (en) | 2001-09-10 | 2001-09-10 | Composition of healthfood for skin-whitening |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030022500A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101318055B1 (en) * | 2011-12-13 | 2013-10-14 | 서림바이오 주식회사 | The composition of milk thistle and isoflavones for treatment and prevention of osteoporosis |
KR20160026576A (en) | 2014-09-01 | 2016-03-09 | 윤정준 | health assistance food having whitening effect and manufacturing method thereof |
CN106811441A (en) * | 2015-11-30 | 2017-06-09 | 台湾粒线体应用技术股份有限公司 | Method of the protection with mitochondria is repaired and promote stem cell proliferation |
CN107865899A (en) * | 2016-09-26 | 2018-04-03 | 台湾粒线体应用技术股份有限公司 | Use of emblic leafflower fruit extract for preparing pharmaceutical composition for protecting mitochondria in retina |
KR101961152B1 (en) * | 2017-11-15 | 2019-03-25 | 주식회사 프롬바이오 | Food composition or cosmetics for whitening, moisturizing or anti-aging of skin with sheep placenta and plant complex |
KR102706369B1 (en) * | 2023-12-18 | 2024-09-12 | 최진원 | Liquid skin lighteining composition comprising glutathione and health functional food having the same |
-
2001
- 2001-09-10 KR KR1020010055613A patent/KR20030022500A/en not_active Application Discontinuation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101318055B1 (en) * | 2011-12-13 | 2013-10-14 | 서림바이오 주식회사 | The composition of milk thistle and isoflavones for treatment and prevention of osteoporosis |
KR20160026576A (en) | 2014-09-01 | 2016-03-09 | 윤정준 | health assistance food having whitening effect and manufacturing method thereof |
CN106811441A (en) * | 2015-11-30 | 2017-06-09 | 台湾粒线体应用技术股份有限公司 | Method of the protection with mitochondria is repaired and promote stem cell proliferation |
CN106811441B (en) * | 2015-11-30 | 2020-12-04 | 台湾粒线体应用技术股份有限公司 | Method for protecting and repairing mitochondria |
CN107865899A (en) * | 2016-09-26 | 2018-04-03 | 台湾粒线体应用技术股份有限公司 | Use of emblic leafflower fruit extract for preparing pharmaceutical composition for protecting mitochondria in retina |
KR101961152B1 (en) * | 2017-11-15 | 2019-03-25 | 주식회사 프롬바이오 | Food composition or cosmetics for whitening, moisturizing or anti-aging of skin with sheep placenta and plant complex |
WO2019098468A1 (en) * | 2017-11-15 | 2019-05-23 | 주식회사 프롬바이오 | Food or cosmetic composition for skin whitening, skin moisturizing, or skin wrinkle improvement, comprising composite of sheep placenta powder and plants |
KR102706369B1 (en) * | 2023-12-18 | 2024-09-12 | 최진원 | Liquid skin lighteining composition comprising glutathione and health functional food having the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6602526B2 (en) | Oral compositions containing lotus | |
KR101702851B1 (en) | The hair follicle and hair growth promoter composition improved with edible crickets | |
WO2018219109A1 (en) | Drug for preventing and treating alopecia | |
KR101776071B1 (en) | Composition containing red sword bean extract for anti-aging and whitening | |
US20170172183A1 (en) | Whitening composition and the use thereof | |
KR101550179B1 (en) | a composite for preventing depilation and growing hair | |
JP2000060482A (en) | Food composition | |
JP2011195504A (en) | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent | |
WO2008034316A1 (en) | Compound preparation capable of reducing oxidative stress rapidly and the preparative method thereof | |
CN104739925A (en) | Composition for treating acnes and preparation method for composition | |
JPH08325156A (en) | Skin preparation for external use, drink and food product containing steviol glycoside | |
US20040214750A1 (en) | Medicaments for healing skin conditions in humans | |
JP2012056919A (en) | Hyaluronic acid production promotor | |
CN104856909A (en) | Sleeping pack capable of reducing melanin sediments and preparation method thereof | |
RU2178660C2 (en) | "milona" curative-sanitation food biologically active additive and method for its obtaining | |
US20060110475A1 (en) | Composition containing in combination at least one bourd oil and at least one borage oil, use thereof as medicine, as dermatological or dermato-cosmetic agent | |
KR20030022500A (en) | Composition of healthfood for skin-whitening | |
JP2011195502A (en) | Fibroblast proliferation promoter, anti-ageing agent and wrinkle-ameliorating agent | |
JP2011136969A (en) | Extract from saussurea involucrata, food/drink composition and basic cosmetic composition each containing the same | |
JP2011195534A (en) | Hyaluronic acid production promoter, anti-ageing agent and wrinkle-ameliorating agent | |
JP2011195532A (en) | Protein glycation inhibitor | |
JP2014208620A (en) | Anti-obesity agent | |
EP1520584A1 (en) | Composition for the activation of the immune system | |
FR2861594A1 (en) | COMPOSITION CONTAINING EXTRACT OF GREEN AND VITAMIN C | |
JP2011195530A (en) | Protein glycation inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Withdrawal due to no request for examination |